Tempus could be the latest breakthrough in cancer diagnosis but, to fully understand the technological and medical advancement that it is, you must first look at one of the co-founders, Eric Lefkofsky.
Eric graduated from the University of Michigan then received his Juris Doctor at the University of Michigan Law School. He is also the author of Accelerated Disruption, works as an adjunct professor at the University of Chicago and established the Lefkofsky Family Foundation with his wife, Liz, to enhance the lives of those in the community they serve. Multiple boards including The Art Institute of Chicago, Lurie Children’s Hospital and The Museum of Science have Eric on their board of trustees and he serves as the Chairman of the Board of Trustees of the Steppenwolf Theatre Company.
While contributing to all of that Eric co-founded his latest enterprise, Tempus. Although, it is not the first company he had been involved in creating. Groupon, Lightbank, Echo Global Logistic, Uptake Technologies and InnerWorkings, to only name a few, have all had Eric contributed their establishment. Tempus is the latest thought, having only been founded a couple years ago in 2015 but has quickly grown into one of the top ten Chicago tech start ups, no small feat.
The goal of Tempus is to collect and analyze large volumes of clinical and molecular data – things like doctors’ notes, diagnosis and lab results – in order to advance cancer treatment. This is beneficial as it allows doctors to work with an extensive amount of information easily in a manner that is less overwhelming, leading to more accurate diagnoses and customizable treatments for patients. Eric’s philanthropic intention shines through this company that could ideally lead to optimal treatment for those diagnosed with cancer and hope for a more advanced approach to medicine.